WAYNE, Pa., Nov. 28 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on November 21, 2008, it received a letter from Nasdaq stating that since it had not yet filed its 10-Q for the quarterly period ended September 30, 2008 as of the date of the letter, it was no longer in compliance with the rules for continued listing according to Marketplace Rule 4310(c)(14).
The Nasdaq letter advised that Encorium had 60 calendar days from the date of the letter to submit a plan to regain compliance. Encorium filed its Form 10-Q for the quarterly period ended September 30, 2008 on Wednesday, November 26, 2008 and has notified Nasdaq of its filing. As a result, the Company anticipates it will receive notice from Nasdaq that it is currently in compliance with Nasdaq Marketplace Rule 4310(c)(14).
About Encorium Group, Inc.
Encorium Group, Inc. is a global clinical research organization
specializing in the design and management of complex clinical trials and
Patient Registries for the pharmaceutical, biotechnology and medical device
industries. The Company's mission is to provide its clients with high quality,
full-service support for their biopharmaceutical and medical device
development programs. Encorium offers therapeutic expertise, experienced team
management and advanced technologies. The Company has drug and biologics
development as well as clinical trial experience across a wide variety of
therapeutic areas such as infectious diseases, cardiovascular, vaccines,
oncology, diabetes endocrinology/metabolism, gene therapy, immunology,
neurology, gastroenterology, dermatology, hepatology, women's health an
|SOURCE Encorium Group, Inc.|
Copyright©2008 PR Newswire.
All rights reserved